SEQUELLA Incorporated

FOR IMMEDIATE RELEASE
May 22, 2006

CONTACT
Rabab Pettitt: 703-739-2424 x108

Sequella Announces Publication of New Diamine Compounds

Scientific Data Published in the Journal of Medicinal Chemistry

Rockville, Md -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for infectious diseases of epidemic potential, announced today it has published an article in the Journal of Medicinal Chemistry. Dr. Elena Bogatcheva is first author on the paper "Identification of New Diamine Scaffolds with Activity Against *Mycobacterium tuberculosis.*"

The full abstract and paper are available on the American Chemical Society (ACS) website at: http://pubs.acs.org/cgi-bin/abstract.cgi/jmcmar/asap/abs/jm050948+.html. The reference details are as follows: Elena Bogatcheva, Colleen Hanrahan, Boris Nikonenko, Rowena Samala, Ping Chen, Jacqueline Gearhart, Francis Barbosa, Leo Einck, Carol A. Nacy, and Marina Protopopova. **Identification of New Diamine Scaffolds with Activity against *Mycobacterium tuberculosis***; *J Med Chem*, ASAP Article 10.1021/jm050948+ S0022-2623(05)00948-9. Web Release Date: April 29, 2006.

Sequella's proprietary new chemical entity (NCE) diamine antibiotics are investigational compounds for the treatment of tuberculosis. Since 2000, Sequella has applied its scientific expertise in tuberculosis research and product development to identify, characterize, and complete the preclinical evaluation of its lead diamine antibiotic drug called SQ109.

SQ109 is a new diamine antibiotic that – if commercialized -- could replace one or more of the current first-line anti-tuberculosis drugs, simplify therapy, and shorten treatment regimens. With a mechanism of action distinct from other antibiotics used in TB therapy (including Isoniazid, Ethambutol and Ethionomide), SQ109 inhibits cell wall synthesis in a select group of microorganisms with excellent *in vitro* activity against both drug susceptible and multi-drug resistant tuberculosis. SQ109 also enhances, both *in vitro* and *in vivo,* the activity of the anti-tubercular drugs Isoniazid and Rifampin, thereby shortening the time required to cure mice of experimental tuberculosis by 25%. Sequella is currently preparing to submit an Investigational New Drug (IND) filing with the FDA and initiate SQ109 clinical trials in the U.S. With this publication Sequella expands its antibiotic pipeline to include several proprietary compound classes for other anti-TB or infectious disease drugs.

About Tuberculosis (TB)
TB is a contagious infectious disease caused by *Mycobacterium tuberculosis*. TB germs can be inhaled into lungs and are able to avoid destruction by certain white blood cells. Without containment by immune cells, the bacteria can spread throughout the body, multiply, survive and remain dormant for years. TB is the leading cause of global deaths that result from a single-agent infectious disease. More than 8 million new cases of active TB disease are reported every year.

About Sequella, Inc.
Sequella is a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. As a catalyst for change, the company leverages its global influence, infectious disease expertise, and diverse product portfolio to pro-actively address emerging health threats with significant market opportunity. Sequella seeks to find the right balance between compassion and competitiveness, the short and the long term. Its lead product candidate, the Transdermal Patch for TB diagnosis, is completing an international Phase III clinical trial. The company expects to file for worldwide registration by 2007. For more information, please visit www.sequella.com

Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

###